We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-14.03%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.07B
AUM Growth
-$246M
Cap. Flow
-$27.7M
Cap. Flow %
-2.58%
Top 10 Hldgs %
57.38%
Holding
61
New
4
Increased
17
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$56M
2
RVMD icon
Revolution Medicines
RVMD
+$38.7M
3
CTMX icon
CytomX Therapeutics
CTMX
+$22M
4
BDTX icon
Black Diamond Therapeutics
BDTX
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$11.4M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$59.5M
2
RCUS icon
Arcus Biosciences
RCUS
+$44M
3
CYTK icon
Cytokinetics
CYTK
+$41.7M
4
BPMC
Blueprint Medicines
BPMC
+$14.7M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
1
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$94M 8.76%
1,583,595
-133,139
-8% -$7.76M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.85B
$91.9M 8.57%
1,944,517
-235,218
-11% -$13.1M
ACIU icon
3
AC Immune
ACIU
$241M
$78.4M 7.31%
11,342,505
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$74.7M 6.96%
2,767,630
-311,525
-10% -$10.2M
XOMA
5
DELISTED
Xoma
XOMA
$56.4M 5.26%
2,773,385
+130,980
+5% +$3.02M
XNCR icon
6
Xencor
XNCR
$1.59B
$50.5M 4.7%
+1,689,300
New +$56M
CYTK icon
7
Cytokinetics
CYTK
$10.9B
$46.4M 4.33%
3,938,280
-3,268,178
-45% -$41.7M
MRUS
8
DELISTED
Merus
MRUS
$42.9M 4%
3,544,654
+375,000
+12% +$5.93M
CALA
9
DELISTED
Calithera Biosciences, Inc
CALA
$42.4M 3.96%
477,982
– –
MTEM
10
DELISTED
Molecular Templates, Inc.
MTEM
$37.9M 3.53%
190,018
-33,871
-15% -$7.42M
RVMD icon
11
Revolution Medicines
RVMD
$40.9B
$30.6M 2.86%
+1,398,070
New +$38.7M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.2B
$30.3M 2.83%
2,674,338
+725,263
+37% +$10.3M
CTMX icon
13
CytomX Therapeutics
CTMX
$714M
$30.1M 2.8%
3,921,973
+3,155,825
+412% +$22M
KURA icon
14
Kura Oncology
KURA
$826M
$24.2M 2.26%
2,434,696
+436,420
+22% +$5M
ANAB icon
15
AnaptysBio
ANAB
$1.63B
$23.9M 2.23%
1,690,237
+750,672
+80% +$11.4M
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.73B
$23.5M 2.19%
2,139,784
+375,000
+21% +$3.52M
REPL icon
17
Replimune Group
REPL
$19.7M 1.84%
1,975,209
-333,900
-14% -$4.98M
FPRX
18
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$17.7M 1.65%
7,783,001
– –
PHAT icon
19
Phathom Pharmaceuticals
PHAT
$731M
$17.5M 1.63%
676,561
-109,290
-14% -$3.65M
CBIO
20
Crescent Biopharma
CBIO
$555M
$16.8M 1.56%
73,618
– –
VSTM icon
21
Verastem
VSTM
$536M
$16.7M 1.56%
527,416
– –
IMVT icon
22
Immunovant
IMVT
$8.11B
$15.6M 1.45%
999,996
– –
INFI
23
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$14.6M 1.36%
17,426,968
– –
MRSN
24
DELISTED
Mersana Therapeutics
MRSN
$13.8M 1.29%
94,896
+47,674
+101% +$8.33M
PVLA
25
Palvella Therapeutics
PVLA
$2.15B
$13.4M 1.25%
73,410
+6,536
+10% +$1.65M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2020 Portfolio in Review

As of Q1 2020, BVF Inc held 61 positions worth $1.07B, down 19% from $1.32B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

BVF Inc's Q1 2020 filing shows 4 new, 17 increased, 18 reduced and 4 closed positions. Its largest new stake was Xencor: 1,689,300 shares worth $50.5M. The largest sale was Arqule Inc, an estimated $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

  • BVF Inc's largest Q1 2020 buy was Xencor: 1,689,300 shares worth $50.5M.
  • BVF Inc added most to CytomX Therapeutics in Q1 2020, an estimated $22M increase.
  • BVF Inc's biggest Q1 2020 reduction was Arcus Biosciences, cutting an estimated $44M.
  • BVF Inc fully exited Arqule Inc in Q1 2020, selling an estimated $59.5M.
  • BVF Inc's ten largest holdings make up 57% of its $1.07B portfolio in Q1 2020.
  • BVF Inc opened 4 new positions and closed 4 in Q1 2020.
  • BVF Inc's portfolio value fell 19% quarter-over-quarter to $1.07B.

Based on BVF Inc's 13F filing for Q1 2020, filed 15 May 2020.